/LEXX
LEXX Stock - Lexaria Bioscience Corp.
Healthcare|BiotechnologyNASDAQ
$0.58-14.96%
$0.10 (-14.96%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.7
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.64
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LEXX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.58 – $0.59
TARGET (TP)$0.67
STOP LOSS$0.54
RISK/REWARD1:2.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.62
52W High$2.43
52W Low$0.48
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $705,923 | $464,278 | $226,208 | $255,397 | $722,738 |
| Gross Profit | $703,203 | $459,456 | $194,708 | $183,556 | $547,392 |
| Gross Margin | 99.6% | 99.0% | 86.1% | 71.9% | 75.7% |
| Operating Income | $-11,880,737 | $-5,753,130 | $-6,534,022 | $-6,619,039 | $-5,686,852 |
| Net Income | $-11,901,841 | $-5,795,345 | $-6,664,899 | $-7,269,324 | $-4,027,006 |
| Net Margin | -1686.0% | -1248.2% | -2946.4% | -2846.3% | -557.2% |
| EPS | $-0.66 | $-0.47 | $-1.01 | $-1.24 | $-0.92 |
Company Overview
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LEXXBeat Rate
36%
Last 14 quarters
Avg Surprise
-14.8%
EPS vs Estimate
Beats / Misses
5/9
Last 12 quarters
Latest EPS
$-0.14
Q4 2025
EPS Surprise History
Q1 24
-18.2%
$-0.13vs$-0.11
Q2 24
+40.0%
$-0.06vs$-0.10
Q3 24
-44.4%
$-0.13vs$-0.09
Q4 24
-36.4%
$-0.15vs$-0.11
Q1 25
-33.3%
$-0.16vs$-0.12
Q2 25
+6.3%
$-0.15vs$-0.16
Q3 25
-40.0%
$-0.21vs$-0.15
Q4 25
+12.5%
$-0.14vs$-0.16
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 13, 2026 | — | — | — | — |
Q1 2026 | Jan 9, 2026 | $-0.17 | — | — | — |
Q4 2025 | Oct 29, 2025 | $-0.16 | $-0.14 | +12.5% | ✓ BEAT |
Q3 2025 | Jul 14, 2025 | $-0.15 | $-0.21 | -40.0% | ✗ MISS |
Q2 2025 | Apr 14, 2025 | $-0.16 | $-0.15 | +6.3% | ✓ BEAT |
Q1 2025 | Jan 10, 2025 | $-0.12 | $-0.16 | -33.3% | ✗ MISS |
Q4 2024 | Nov 26, 2024 | $-0.11 | $-0.15 | -36.4% | ✗ MISS |
Q3 2024 | Jul 12, 2024 | $-0.09 | $-0.13 | -44.4% | ✗ MISS |
Q2 2024 | Apr 9, 2024 | $-0.10 | $-0.06 | +40.0% | ✓ BEAT |
Q1 2024 | Jan 12, 2024 | $-0.11 | $-0.13 | -18.2% | ✗ MISS |
Q4 2023 | Nov 21, 2023 | $-0.17 | $-0.12 | +29.4% | ✓ BEAT |
Q3 2023 | Jul 14, 2023 | $-0.25 | $-0.37 | -48.0% | ✗ MISS |
Q2 2023 | Apr 14, 2023 | — | $-0.22 | — | — |
Q1 2023 | Jan 17, 2023 | — | $-0.30 | — | — |
Q4 2022 | Nov 25, 2022 | $-0.21 | $-0.24 | -14.3% | ✗ MISS |
Q3 2022 | Jul 14, 2022 | $-0.28 | $-0.41 | -46.4% | ✗ MISS |
Q2 2022 | Apr 11, 2022 | $-0.21 | $-0.25 | -19.0% | ✗ MISS |
Q1 2022 | Jan 14, 2022 | — | $-0.35 | — | — |
Q4 2021 | Nov 29, 2021 | $-0.23 | $-0.22 | +4.3% | ✓ BEAT |
Q3 2021 | Jul 15, 2021 | — | $-0.40 | — | — |
Latest News
Lexaria Bioscience shares are trading lower after the company announced a $3.5 million registered direct offering of 2.66 million shares at a price of $1.315 per share.
📉 NegativeBenzinga•Dec 15, 2025, 05:10 PM
UPDATE: Lexaria Bioscience Announces $3.5M Registered Direct Offering Of 2,661,600 Shares At A Price Of $1.315/Share
📉 NegativeBenzinga•Dec 15, 2025, 01:51 PM
Lexaria Bioscience Announces $3.5M Registered Direct Offering Priced At-The-Market
➖ NeutralBenzinga•Dec 15, 2025, 01:04 PM
Lexaria Extends Partnership With PharmaCO To April 2026 For Ongoing Evaluation Of DehydraTECH, Following Australian Study Data Review
📈 PositiveBenzinga•Nov 12, 2025, 02:12 PM
Lexaria Awarded 4 New Patents Covering Therapeutics For Diabetes, Hypertension, Seizure Disorders, And Antiviral Treatments
📈 PositiveBenzinga•Oct 9, 2025, 01:23 PM
Lexaria Bioscience shares are trading lower after the company announced it price its $4 million registered direct offering at $1.50 per share with $1.34 warrants in a concurrent private placement.
📉 NegativeBenzinga•Sep 26, 2025, 01:29 PM
Lexaria Bioscience Prices $4M Registered Direct Offering At $1.50/Share With $1.37 Warrants In Concurrent Private Placement
➖ NeutralBenzinga•Sep 26, 2025, 12:25 PM
Lexaria Bioscience announces ~$4M registered direct offering of shares
➖ NeutralSeeking Alpha•Sep 26, 2025, 12:18 PM
Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading
📈 PositiveSeeking Alpha•Sep 26, 2025, 09:30 AM
Effective September 19, 2025, Lexaria Bioscience Terminated The Capital On Demand Sales Agreement With JonesTrading Institutional Services
📉 NegativeBenzinga•Sep 25, 2025, 09:21 PM
Lexaria Bioscience Announces Results From Fluorescently Tagged Semaglutide Rodent Biodistribution Study
➖ NeutralBenzinga•Sep 19, 2025, 03:22 PM
Lexaria Bioscience announces $2M registered direct offering; shares slip 19%
📉 NegativeSeeking Alpha•Apr 25, 2025, 01:19 PM
Frequently Asked Questions about LEXX
What is LEXX's current stock price?
Lexaria Bioscience Corp. (LEXX) is currently trading at $0.58 per share. The stock has moved -14.96% today.
What is the analyst price target for LEXX?
No analyst price targets are currently available for this stock.
What sector is Lexaria Bioscience Corp. in?
Lexaria Bioscience Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LEXX's market cap?
Lexaria Bioscience Corp. has a market capitalization of $0.01 billion, making it a small-cap company.
Does LEXX pay dividends?
No, Lexaria Bioscience Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALLR
Allarity Therapeutics, Inc.
$1.03
Mkt Cap: $0.0B
BCTX
BriaCell Therapeutics Corp.
$8.95
Mkt Cap: $0.0B
CASI
CASI Pharmaceuticals, Inc.
$0.81
Mkt Cap: $0.0B
CING
Cingulate Inc.
$3.97
Mkt Cap: $0.0B
CLSD
Clearside Biomedical, Inc.
$1.00
Mkt Cap: $0.0B
CRIS
Curis, Inc.
$1.07
Mkt Cap: $0.0B
ENTO
Entero Therapeutics, Inc.
$1.98
Mkt Cap: $0.0B
HOTH
Hoth Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
LIXT
Lixte Biotechnology Holdings, Inc.
$4.32
Mkt Cap: $0.0B
PCSA
Processa Pharmaceuticals, Inc.
$3.78
Mkt Cap: $0.0B
Explore stocks similar to LEXX for comparison